- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.11. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11. | Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share | 1 | Seeking Alpha | ||
| 21.11. | Inhibikase Therapeutics prices $100 million public offering | 1 | Investing.com | ||
| 21.11. | Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 20.11. | Inhibikase Therapeutics announces proposed public offering and pre-funded warrants | 1 | Seeking Alpha | ||
| 20.11. | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | 99 | GlobeNewswire (Europe) | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| 14.11. | Inhibikase Therapeutics GAAP EPS of -$0.13 | 2 | Seeking Alpha | ||
| 14.11. | Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | 845 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.11. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.08. | Inhibikase taps commercial chief from Pfizer, Gilead to pave the way for PAH launch | 31 | FiercePharma | ||
| 19.08. | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 355 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 15.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 | 1 | Seeking Alpha | ||
| 14.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 211 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 30.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 492 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 252 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 191,60 | +0,21 % | AbbVie: Top-Pick für Pharma-Anleger? | Die Aktie von AbbVie hat sich 2025 zu einem der auffälligsten Lichtblicke im sonst schwächelnden Pharmasektor entwickelt. Während viele Gesundheitswerte unter dem Druck neuer Technologie-Hypes litten... ► Artikel lesen | |
| TEVA | 26,000 | +1,17 % | Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 | TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial... ► Artikel lesen | |
| EYEPOINT | 14,595 | +2,82 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| ORGANIGRAM GLOBAL | 1,860 | +3,33 % | OrganiGram: Umsatzsprung im vierten Quartal treibt Aktie vorbörslich an | ||
| QUANTUM BIOPHARMA | 7,150 | +1,42 % | Quantum BioPharma Ltd.: Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update | Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 12,750 | +0,79 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| AMARIN | 11,800 | +0,85 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 38,200 | -1,04 % | XFRA ITH0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEKTAR THERAP. NEW... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 143,40 | +2,06 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming Investor Events | DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:
Zanidatamab HERIZON-GEA-01... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,788 | -0,78 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 464,00 | -0,24 % | Sagimet rises as licensing deal with Teva unit targets Madrigal drug | ||
| XORTX THERAPEUTICS | 0,506 | -0,39 % | XORTX Therapeutics Inc.: XORTX Announces Closing of US$1.1 Million Registered Direct Offering | CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 62,90 | -0,25 % | Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating | ||
| OPUS GENETICS | 1,772 | +2,67 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| RIGEL PHARMACEUTICALS | 35,600 | -0,56 % | Rigel Pharmaceuticals, Inc.: Rigel Announces Publication of Final 5-year Data on REZLIDHIA (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology | Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +1,89 % bei einem Aktienkurs von 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.